Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

Eli Lilly (NYSE: LLY) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly is setting the stage for a strong 2025, with its fourth-quarter results and forward guidance reflecting solid ...

Another eventful morning for the stock market: not only do we continue into the heart of Q4 earnings season, but today is Thursday, so generally the morning we see Weekly Jobless Claims. A quarterly ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

Stock futures are slightly higher Thursday morning after two straight days of gains have taken major indexes back near all-time highs.

Eli Lilly and Co (NYSE:LLY) stock is trading higher after the company released better-than-expected fourth-quarter earnings ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Eli Lilly & Co (LLY – Research Report).